Physician profile
Malwinder Singh
NPI 1871558791
$1,429.59
in general payments reported to CMS, 2019-2025
12 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $72.88 · 2021: $107 · 2022: $177 · 2023: $150 · 2024: $134 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $238.62 | 2019 | |
| Glaxosmithkline, LLC. | $229.58 | 2019 | |
| Boston Scientific Corporation | $177.96 | 2019-2023 | Watchman Flx |
| Neurocrine Biosciences, INC. | $177.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.85 | 2019 | |
| Gilead Sciences, INC. | $120.29 | 2024 | Biktarvy |
| Shionogi INC | $110.16 | 2025 | Fetroja |
| Teva Pharmaceuticals USA, INC. | $107.24 | 2021 | |
| Abbott Laboratories | $72.88 | 2020 | |
| Fisher Scientific Company L.L.C. | $37.46 | 2019 | |
| Abiomed | $19.68 | 2025 | |
| Werfen USA LLC | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malwinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.